What is ARA-290?
ARA-290, also called cibinetide, was born from a clever observation about erythropoietin (EPO), the hormone famous for building red blood cells: EPO also carries a second, separate signal that protects and repairs tissue. Researchers set out to split the two, and ARA-290 is the result, a small peptide engineered to deliver the repair signal without touching red blood cell counts.
That gives it a precise niche. Rather than a general recovery compound, ARA-290 is a nerve-repair candidate with a defined pathway, and nearly all of its human research targets one specific problem: small fiber neuropathy, damage to the tiny nerve fibers that carry pain and sensation.
How does it work?
ARA-290 engages what researchers call the innate repair receptor, a signaling complex the body activates to protect tissue and calm local inflammation after injury. Through that receptor, the peptide is proposed to support the survival and regrowth of small nerve fibers while settling the inflammatory environment around them.
The preclinical work that motivated human testing showed exactly that profile, including reduced allodynia, the heightened pain response of damaged nerves, in animal neuropathy models. A plausible mechanism is not a proven effect, and ARA-290 belongs to the small club of peptides that carried its mechanism into placebo-controlled human trials.
Why it matters
Small fiber neuropathy is miserable and underserved: burning pain, strange sensations, autonomic trouble, and a medicine cabinet that mostly masks symptoms rather than repairing fibers. A compound with placebo-controlled evidence of nerve regrowth, not just symptom relief, would be a genuinely new kind of tool, and that objective-endpoint story is exactly what makes ARA-290 stand out in this library.
What the trials showed
The human record is early, narrow, and unusually concrete. A 2012 randomized, double-blind pilot in sarcoidosis patients with small fiber neuropathy found ARA-290 safe and associated with improved neuropathic symptoms. A 2013 randomized trial replicated the symptom benefit and added the key measurement: increased corneal nerve fiber density, a physical, countable marker of nerve regeneration visible in the eye.
A larger 2017 multicentre randomized trial (NCT02039687), a four-arm phase 2 dose-ranging study, focused on that objective endpoint and reported improved corneal nerve fiber abundance in the same population. Three placebo-controlled trials, one patient population, symptoms plus a physical regrowth marker moving together: that is a real signal, concentrated in sarcoidosis patients, with early diabetes work (NCT01933529) extending the mechanism.
What people notice in practice
ARA-290 circulates in neuropathy communities well beyond sarcoidosis, and what users report, labeled honestly as experience rather than trial evidence, tracks the trial profile: burning and stabbing sensations easing over weeks of daily dosing, better sensation, sometimes calmer autonomic symptoms. Neuropathic pain fluctuates and responds to expectation, and the populations self-treating, diabetic and idiopathic neuropathy mostly, are adjacent to rather than inside the trial evidence.
The pros and the cons
What's promising
- Placebo-controlled human trials, three of them, all pointing the same way.
- An objective endpoint: physically measured nerve fiber regrowth, not just symptom scores.
- A defined mechanism deliberately separated from EPO's blood-building effects.
- Good safety reporting across the trials.
What's uncertain
- The evidence is concentrated in one population: sarcoidosis-associated small fiber neuropathy.
- Trials are pilot and phase 2 scale; no phase 3 exists.
- Common self-treated neuropathies, diabetic above all, sit outside the trial evidence.
- No approval anywhere, and development momentum has slowed.
Worth considering
- Neuropathy deserves a diagnostic workup first; small fiber neuropathy has findable causes.
- The trial dosing was daily subcutaneous injection over weeks; practice mimics it loosely.
- Sourcing quality is the standing gray-market question.
- A physician tracking objective measures beats symptom-chasing alone.
Why the evidence stopped at phase 2
ARA-290 had a sponsor and a program, and the program slowed the way small-biotech programs do: funding cycles, strategic pivots, the long expensive road from phase 2 signals to phase 3 proof in a niche indication. The science did not fail; the phase 3 that would settle it has simply never been run. For a compound whose phase 2 record includes objective nerve regrowth, that is one of the more frustrating stalls in this library.
What the key trials tested
Our framing rule for evidence: a trial tests one dose, one duration, one population, one endpoint. Where the evidence sits:
Preclinical & practice
The innate-repair-receptor mechanism work, and self-treatment in broader neuropathies.
Early trials
Three placebo-controlled trials in sarcoidosis small fiber neuropathy; early diabetes work.
Late-stage trials
None.
Approved uses
None, anywhere.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
How is ARA-290 related to EPO?
It is EPO's repair signal with the blood-building stripped out. Researchers noticed erythropoietin protects tissue through a separate receptor complex from the one that raises red blood cells, and engineered a small peptide that touches only the repair side. That separation matters: raising red cell counts in someone who does not need it carries real cardiovascular risk.
What is corneal nerve fiber density, and why does it matter?
The cornea is the one place in the body where small nerve fibers can be photographed and counted noninvasively, so it serves as a window on small fiber health everywhere. Two of the three trials found ARA-290 increased that density, physical evidence of regrowth rather than just patients feeling better. Objective endpoints like that are rare and precious in peptide research.
Does it work for diabetic neuropathy?
Unproven. The placebo-controlled evidence is in sarcoidosis-associated small fiber neuropathy, with early work extending the mechanism toward diabetes but no completed efficacy trial there. The mechanism is not disease-specific, which makes extrapolation tempting, and tested-in-sarcoidosis is the honest label on everything this peptide has shown.
Is ARA-290 safe?
Across the three controlled trials it was reported as safe and well tolerated, with the deliberate advantage that it does not raise red blood cell counts the way EPO does. The record covers weeks of dosing in trial settings; long-term use and gray-market sourcing carry the usual open questions.
What to take away
If you remember five things from this article, make them these:
- ARA-290 is EPO's tissue-repair signal isolated into a peptide, with the blood effects engineered out.
- It carries something rare here: three placebo-controlled human trials, all favorable.
- The standout evidence is objective, measured regrowth of nerve fibers, not just symptom scores.
- All of it is phase 2 scale in one population; the phase 3 never came.
- Neuropathy deserves diagnosis first, and any ARA-290 conversation belongs with the physician doing that work.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. ARA-290 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.